Indeed, this trial showed that once-weekly subcutaneous semaglutide (at the maximum tolerated dose) improves glucose control (as assessed by TIR and HbA1c) —without increasing the time spent in hypoglycemia— and reduces insulin requirements as well as carbohydrate intake, body weight, BMI, and waist and hip circumferences in adults with T1D using an AID system. The gene discussed is INS; the disease is Hypoglycemia.